AstraZeneca

The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.

AstraZeneca's Imfinzi shows positive results for bladder cancer; Apple receives FDA approval for hearing aid software on earbuds.

Sanofi and AstraZeneca are shipping Beyfortus doses to the U.S. ahead of the RSV season, with FDA clearance for a new manufacturing line. Despite initial supply issues, Sanofi aims to meet demand through additional production lines and a reservation system for private healthcare providers.

Sanofi is shipping BEYFORTUS doses in the US to ensure every eligible baby has access to immunization against RSV. A new filling line for BEYFORTUS has been approved by the FDA to expand manufacturing capacity. BEYFORTUS is the first long-acting monoclonal antibody for preventing RSV lower respiratory tract disease in newborns and infants up to 24 months.

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of scraping tools. Account usually reactivates within 24 hours; contact support if still disabled.

Imfinzi plus Imjudo combo significantly improved five-year overall survival rates in unresectable hepatocellular carcinoma patients compared to sorafenib, with 19.6% surviving vs. 9.4%.

The Renal Cell Carcinoma Clinical Trial Pipeline Market is projected to grow significantly from 2024 to 2031, driven by technological innovations, rising demand, and regulatory changes. The market is segmented by type and application, with key players including Amgen, AstraZeneca, and Pfizer. Clinical trials focus on novel therapies, drug combinations, and targeted treatments, aiming to improve outcomes for renal cell carcinoma patients.

Drugmakers like Bristol Myers Squibb, AstraZeneca, and Eli Lilly invest billions in radiopharmaceuticals, which deliver radiation directly to tumors. These drugs, in development for various cancers, attach radioactive material to targeting molecules, sparing healthy cells. Novartis' successes with Lutathera and Pluvicto have spurred interest, but manufacturing and logistics remain complex. The market potential ranges from $5 billion to tens of billions, depending on efficacy across cancer types.

Sanofi ships BEYFORTUS doses in the US to protect eligible babies against RSV, with a new FDA-approved filling line expanding manufacturing capacity. BEYFORTUS is the first long-acting monoclonal antibody for RSV prevention in newborns and infants up to 24 months.